###### Key messages

-   The complexity and morbidity associated with lupus nephritis underscore the importance of determining factors that predict response to therapy.

-   Among patients who continued into the maintenance phase of ALMS, baseline eGFR \>90 ml/min/1.73 m^2^ and UP/C \<1 at the end of induction were independently associated with complete remission during the maintenance phase. Induction treatment with intravenous cyclophosphamide was associated with a lower likelihood of treatment failure.

-   Among patients who continued into the maintenance phase of ALMS, lack of treatment with anti-malarials, failure to reduce anti-dsDNA or UP/C within 8 weeks of induction, and positive anti-dsDNA at the end of induction were independently associated with treatment failure.

Introduction {#s1}
============

Lupus nephritis continues to be a major source of morbidity and mortality in patients with systemic lupus erythematosus, with 10%--15% of patients ultimately progressing to end-stage renal disease.[@R1] The variability of treatment regimens and time to treatment response along with the heterogeneous and unpredictable course of lupus nephritis underscore the importance of identifying factors that are associated with response to therapy. We previously identified several clinical and serological characteristics that were associated with response to treatment during the 6-month induction phase of the Aspreva Lupus Management Study (ALMS), a randomised controlled trial of 370 patients with class III--V lupus nephritis.[@R2] Although renal response at 6 months is an important endpoint, there is a greater clinical need to determine factors that are associated with long-term renal outcomes. ALMS provides an excellent opportunity to begin to address this issue because the study included a 36-month maintenance phase that followed completion of induction therapy. The analyses presented here examine factors that are associated with clinical outcome for all 370 subjects who entered ALMS (complete population) as well as for the 227 subjects who continued into the maintenance phase (maintenance population). Analyses were performed separately within these two populations because the patients comprising the two populations were very distinct. Only those patients who achieved a renal response at the end of the induction phase were eligible to enter into the maintenance phase of the trial.

Patients and methods {#s2}
====================

Study design {#s2a}
------------

ALMS was a randomised, open-label, multinational, multicentre trial of mycophenolate mofetil (MMF) versus pulse intravenous cyclophosphamide (IVC) for induction therapy of lupus nephritis followed by a randomised, double-blind comparison of MMF versus azathioprine (AZA) for maintenance therapy in those patients who responded to induction.[@R3] Importantly, subjects who did not meet criteria for renal response at week 24 were withdrawn from the trial. The institutional review boards at each participating centre approved the study. All of the study subjects gave written informed consent prior to randomisation into the study.

Details of the study design have been previously published.[@R4] In brief, eligible patients had biopsy-proven class III--V lupus nephritis within 6 months of study entry and laboratory tests consistent with active nephritis, including evidence of an active urine sediment, proteinuria ≥1 g/day or elevated serum creatinine (\>1.3 mg/dL). Patients with class III or V lupus nephritis were required to have higher levels of proteinuria (≥2 g/day) or serum creatinine \>1.3 mg/dL. Only patients who met prespecified criteria for a complete or partial renal response after 24 weeks of induction therapy and were adjudicated as responders by the clinical endpoints committee (CEC) were advanced into the maintenance phase of the trial.

ALMS outcome measures {#s2b}
---------------------

Renal response at 6 months of the induction phase was defined as a decrease in the urine protein:creatinine ratio (UP/C) on a 24 h collection to \<3 in patients with baseline nephrotic-range proteinuria (UP/C \>3) or by ≥50% in patients with subnephrotic-range proteinuria and stabilisation or improvement in serum creatinine levels. Complete renal remission in ALMS was defined as UP/C ≤500 mg on a 24 h collection, an inactive urine sediment and serum creatinine level within 25% of baseline. Complete renal remission was assessed at any time during the maintenance phase. Patients might have achieved complete remission at the end induction and remained in complete remission or, alternatively, achieved a partial remission at the end of induction and later developed a complete remission. Renal response (complete or partial) was required for entry into the maintenance phase of the trial. The primary outcome measure in the maintenance phase was the time to treatment failure (TF), defined by any of the following criteria as adjudicated by a CEC: (1) death, (2) end-stage renal disease, (3) sustained doubling of serum creatinine, (4) renal flare, (5) requirement for rescue therapy. The definitions of renal flare were: *Proteinuric renal flare*: doubling of the UP/C and proteinuria (≥1 g of protein per 24 h in patients with urinary protein clearance of ≤0.5 g per 24 h at the end of induction and ≥2 g per 24 h in patients with urinary protein clearance of \>0.5 g per 24 h at the end of induction).*Nephritic renal flare*: increase of 25% or more in the lowest serum creatinine level during the period from screening to the end of induction plus one or more of the following findings: simultaneous doubling of urinary protein clearance, reaching a minimum of 2 g per 24 h (or the UP/C equivalent); new or increased haematuria (≥5 red cells per high-power field or ≥2+ on a dipstick test for blood); or the appearance of cellular casts.

Baseline factors associated with renal outcome {#s2c}
----------------------------------------------

We analysed several baseline (start of induction) demographic, clinical, serological and histopathological factors to determine whether they were associated with TF or complete renal remission during the maintenance phase. These characteristics included race, ethnicity, age, biopsy class, duration of lupus nephritis, estimated glomerular filtration rate (eGFR), anti-double-stranded DNA (anti-dsDNA) antibody level, C3 and C4 complement levels, 24 h UP/C, induction treatment (IVC or MMF) and use of antimalarials or statins. We examined these factors separately within the complete population and within the maintenance population. The characteristics of the complete and maintenance populations are described in [table 1](#LUPUS2015000089TB1){ref-type="table"}.

###### 

Demographic and disease characteristics (populations: complete ITT population and maintenance population)

                                               Complete population (N=370) n (%)   Maintenance population (N=227) n (%)
  -------------------------------------------- ----------------------------------- --------------------------------------
  Race                                         370 (100.0)                         227 (100.0)
   Caucasian                                   147 (39.7)                          99 (43.6)
   Black                                       46 (12.4)                           23 (10.1)
   Asian                                       123 (33.2)                          76 (33.5)
   Other                                       54 (14.6)                           29 (12.8)
  Ethnicity                                    370 (100.0)                         227 (100.0)
   Hispanic                                    131 (35.4)                          77 (33.9)
   Non-Hispanic                                239 (64.6)                          150 (66.1)
  Age at randomisation (years)                 370 (100.0)                         227 (100.0)
   ≤20                                         50 (13.5)                           35 (15.4)
   \>20 and ≤30                                124 (33.5)                          73 (32.2)
   \>30 and ≤40                                120 (32.4)                          77 (33.9)
   \>40                                        76 (20.5)                           42 (18.5)
  Biopsy class                                 370 (100.0)                         227 (100.0)
   III/IV                                      260 (70.3)                          169 (74.4)
   III/V or IV/V                               50 (13.5)                           23 (10.1)
   V                                           60 (16.2)                           35 (15.4)
  Lupus nephritis duration (years)             370 (100.0)                         227 (100.0)
   ≤1                                          236 (63.8)                          155 (68.3)
   \>1 and \<5                                 69 (18.7)                           31 (13.7)
   ≥5                                          65 (17.6)                           41 (18.1)
  eGFR baseline (mL/min/1.73 m^2^)             332 (100.0)                         227 (100.0)
   \<90                                        188 (56.6)                          131 (57.7)
   ≥90                                         144 (43.4)                          96 (42.3)
  Anti-dsDNA baseline (IU/mL)                  325 (100.0)                         222 (100.0)
   Negative (\<30)                             14 (4.3)                            14 (6.3)
   Positive (≥30)                              311 (95.7)                          208 (93.7)
  C3 baseline (mg/dL)                          328 (100.0)                         224 (100.0)
   ≥90                                         80 (24.4)                           50 (22.3)
   \<90                                        248 (75.6)                          174 (77.7)
  C4 baseline (mg/dL)                          327 (100.0)                         223 (100.0)
   ≥16                                         111 (33.9)                          70 (31.4)
   \<16                                        216 (66.1)                          153 (68.6)
  UP/C baseline                                325 (100.0)                         223 (100.0)
   ≤1                                          53 (16.3)                           33 (14.8)
   \>1 and ≤3                                  123 (37.8)                          88 (39.5)
   \>3                                         149 (45.9)                          102 (45.7)
  Antimalarial treatment                       370 (100.0)                         227 (100.0)
   Concomitant treatment with anti-malarials   127 (34.3)                          84 (37.0)
   No antimalarial treatment                   243 (65.7)                          143 (63.0)
  Lipid-modifying agent treatment              370 (100.0)                         227 (100.0)
   Statin                                      85 (23.0)                           52 (22.9)
   No statin                                   285 (77.0)                          175 (77.1)
  Induction treatment                          370 (100.0)                         227 (100.0)
   MMF                                         185 (50.0)                          120 (52.9)
   IVC                                         185 (50.0)                          107 (47.1)

Anti-dsDNA, anti-double-stranded DNA; eGFR, estimated glomerular filtration rate; ITT, intention to treat; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; UP/C, urine protein:creatinine ratio.

Changes in factors during the induction phase {#s2d}
---------------------------------------------

In addition to the baseline variables described above, we sought to determine if changes in biological factors during the induction phase were associated with TF or complete renal remission during the maintenance phase. We examined reduction in proteinuria, reduction in anti-dsDNA levels and improvement in C3 and C4 from baseline to week 8 in both the complete and maintenance populations. We chose the time point of week 8 for two reasons: (1) we wanted to understand whether changes in biological factors very early in the induction period were associated with renal response during the maintenance phase, and (2) we wanted to be consistent with the methodology of our original manuscript in which we demonstrated that normalisation of complement by week 8 and/or reduction in proteinuria by week 8 were associated with renal response at the end of induction at week 24. In the analysis of the maintenance population, we also assessed anti-dsDNA positivity, eGFR, proteinuria and complement levels at the end of induction. Normalisation of complement was defined as a C3 level of \<90 mg/dL or a C4 level of \<16 mg/dL at baseline with the corresponding week 8 value being ≥90 mg/dL (C3) or ≥16 mg/dL (C4). Reduction in proteinuria was defined as a decrease of ≥25%. Reduction in anti-dsDNA was defined as a decline to ≤60 IU/mL for subjects with baseline anti-dsDNA of \>200 IU/mL or to ≤30 IU/mL for subjects with baseline anti-dsDNA of \>30 IU/mL and ≤200 IU/mL.

Statistical methods {#s2e}
-------------------

The number and percentage of successes and failures were calculated for each level of each covariate for both treatment outcome variables along with univariate ORs, 95% CIs and p values. These univariate analyses were performed on all the patients randomised into the ALMS (complete population, n=370) and for all the patients who finished the induction phase and entered the maintenance phase (maintenance population, n=227). For the complete population analyses (n=370), patients not randomised into the maintenance phase were assumed to have a treatment outcome of either TF or non-complete remission as appropriate. Factors showing a significant (p\<0.05) association with treatment outcome are discussed in the Results section.

In order to ascertain the extent to which the various factors were independent of each other, a multivariate logistic regression analysis was conducted. To avoid multicollinearity, a correlation matrix was produced for all variables; groups of covariates that were correlated with each other (Pearson\'s rank correlation \>0.7) were inspected, and only the variable most highly correlated with treatment outcome was put forward into the multivariate analysis.

The multivariate analysis was repeated for each population and each treatment outcome, with three methods of selecting variables used: forward selection, backward elimination and stepwise. Different methods were used to check for consistency, with the stepwise procedure being the primary method. Variables were entered into the multivariate model (forward and stepwise selection methods only) if they were significant at the 0.1 level and left the model (backward and stepwise selection methods only) if they became non-significant at that level.

In the analysis of the complete population, the following variables were available for selection into the multivariate model for TF and complete remission: all demographic and disease characteristic variables, UP/C reduction at week 8, anti-dsDNA reduction at week 8, C3 normalisation at week 8, C4 normalisation at week 8 and normalisation of both C3 and C4 by week 8. For the analysis of the maintenance population, the following additional variables, measured at the end of the induction phase, were used in the multivariate analysis: UP/C, anti-dsDNA, C3, C4 and eGFR. Following correlation analysis, the normalisation of both C3 and C4 by week 8 was omitted from the maintenance population multivariate analyses.

Presence of covariates in the various multivariate models indicates that they are independent predictors of treatment outcome. While covariates remain in the models if they show significance at the p\<0.1 level, only those with p\<0.05 are discussed in the Results section.

Results {#s3}
=======

The ALMS demonstrated that there was no difference in efficacy between MMF and IVC for the induction treatment of lupus nephritis at 24 weeks.[@R3] However, during the subsequent 36-month maintenance phase, MMF was shown to be superior to AZA in preventing TF in patients who initially responded to induction therapy.[@R5]

[Tables 2](#LUPUS2015000089TB2){ref-type="table"} and [3](#LUPUS2015000089TB3){ref-type="table"} show the results of the univariate analyses for the baseline characteristics examined. [Table 4](#LUPUS2015000089TB4){ref-type="table"} shows the results of the univariate analyses of clinical changes that occurred during induction therapy. [Table 5](#LUPUS2015000089TB5){ref-type="table"} shows the results of the multivariate analysis.

###### 

Univariate baseline parameters associated with renal outcome (population: complete population (n=370))

                                                                   Treatment failure   Complete renal remission                                              
  ---------------------------------------------------------------- ------------------- -------------------------- ---------- ------------ ------------------ --------
  Race                                                                                                                                                       
   Caucasian (ref)                                                 75 (51.0)                                                 59 (40.1)                       
   Black                                                           31 (67.4)           2.0 (1.0 to 4.0)           0.0538     13 (28.3)    0.6 (0.3 to 1.2)   0.1487
   Asian                                                           62 (50.4)           1.0 (0.6 to 1.6)           0.9200     49 (39.8)    1.0 (0.6 to 1.6)   0.9602
   Other                                                           30 (55.6)           1.2 (0.6 to 2.2)           0.5685     17 (31.5)    0.7 (0.4 to 1.3)   0.2634
  Ethnicity                                                                                                                                                  
   Hispanic (ref)                                                  78 (59.5)                                                 42 (32.1)                       
   Non-Hispanic                                                    120 (50.2)          0.7 (0.4 to 1.1)           0.0858     96 (40.2)    1.4 (0.9 to 2.2)   0.1238
  Age at randomisation (years)                                                                                                                               
   ≤20 (ref)                                                       29 (58.0)                                                 20 (40.0)                       
   \>20 and ≤30                                                    69 (55.6)           0.9 (0.5 to 1.8)           0.7769     38 (30.6)    0.7 (0.3 to 1.3)   0.2376
   \>30 and ≤40                                                    60 (50.0)           0.7 (0.4 to 1.4)           0.3421     51 (42.5)    1.1 (0.6 to 2.2)   0.7633
   \>40                                                            40 (52.6)           0.8 (0.4 to 1.7)           0.5539     29 (38.2)    0.9 (0.4 to 1.9)   0.8356
  Biopsy class                                                                                                                                               
   III/IV (ref)                                                    129 (49.6)                                                105 (40.4)                      
   III/V or IV/V                                                   35 (70.0)           2.4 (1.2 to 4.5)           0.0095     11 (22.0)    0.4 (0.2 to 0.8)   0.0161
   V                                                               34 (56.7)           1.3 (0.8 to 2.3)           0.3256     22 (36.7)    0.9 (0.5 to 1.5)   0.5959
  Lupus nephritis duration (years)                                                                                                                           
   ≤1 (ref)                                                        119 (50.4)                                                95 (40.3)                       
   \>1 and \<5                                                     44 (63.8)           1.7 (1.0 to 3.0)           0.0521     19 (27.5)    0.6 (0.3 to 1.0)   0.0567
   ≥5                                                              35 (53.8)           1.1 (0.7 to 2.0)           0.6251     24 (36.9)    0.9 (0.5 to 1.5)   0.6268
  eGFR baseline (mL/min/1.73 m^2^)                                                                                                                           
   \<90 (ref)                                                      88 (46.8)                                                 76 (40.4)                       
   ≥90                                                             72 (50.0)           1.1 (0.7 to 1.8)           0.5642     62 (43.1)    1.1 (0.7 to 1.7)   0.6299
  Anti-dsDNA baseline (IU/mL)                                                                                                                                
   Negative (\<30) (ref)                                           1 (7.1)                                                   8 (57.1)                        
   Positive (≥30)                                                  157 (50.5)          13.3 (1.7 to 103)          0.0133     128 (41.2)   0.5 (0.2 to 1.5)   0.2427
  C3 baseline (mg/dL)                                                                                                                                        
   ≥90 (ref)                                                       43 (53.8)                                                 32 (40.0)                       
   \<90                                                            115 (46.4)          0.7 (0.4 to 1.2)           0.2517     106 (42.7)   1.1 (0.7 to 1.9)   0.6658
  C4 baseline (mg/dL)                                                                                                                                        
   ≥16 (ref)                                                       53 (47.7)                                                 45 (40.5)                       
   \<16                                                            104 (48.1)          1.0 (0.6 to 1.6)           0.9453     92 (42.6)    1.1 (0.7 to 1.7)   0.7224
  UP/C baseline                                                                                                                                              
   ≤1 (ref)                                                        27 (50.9)                                                 23 (43.4)                       
   \>1 and ≤3                                                      59 (48.0)           0.9 (0.5 to 1.7)           0.7168     59 (48.0)    1.2 (0.6 to 2.3)   0.5772
   \>3                                                             70 (47.0)           0.9 (0.5 to 1.6)           0.6198     54 (36.2)    0.7 (0.4 to 1.4)   0.3578
  Antimalarial treatment concomitantly during induction                                                                                                      
   Antimalarial (ref)                                              61 (48.0)                                                 56 (44.1)                       
   No antimalarial                                                 137 (56.4)          1.4 (0.9 to 2.2)           0.1270     82 (33.7)    0.6 (0.4 to 1.0)   0.0513
  Lipid-modifying agent treatment concomitantly during induction                                                                                             
   Statin (ref)                                                    47 (55.3)                                                 33 (38.8)                       
   No statin                                                       151 (53.0)          0.9 (0.6 to 1.5)           0.7083     105 (36.8)   0.9 (0.6 to 1.5)   0.7403
  Induction treatment                                                                                                                                        
   MMF (ref)                                                       99 (53.5)                                                 72 (38.9)                       
   IVC                                                             99 (53.5)           1.0 (0.7 to 1.5)           \>0.9999   66 (35.7)    0.9 (0.6 to 1.3)   0.5190

Percentages show the proportion of TFs or complete remitters within the applicable covariate category.

Ref: reference category for ORs.

ORs \>1 imply more TF or complete remission in comparison category than in reference category.

Anti-dsDNA, anti-double-stranded DNA; eGFR, estimated glomerular filtration rate; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; TF, treatment failure; UP/C, urine protein:creatinine ratio.

###### 

Univariate baseline parameters associated with renal outcome (population: maintenance population (n=227))

                                                                   Treatment failure   Complete renal remission                                            
  ---------------------------------------------------------------- ------------------- -------------------------- -------- ------------ ------------------ ----------
  Race                                                                                                                                                     
   Caucasian (ref)                                                 27 (27.3)                                               59 (59.6)                       
   Black                                                           8 (34.8)            1.4 (0.5 to 3.7)           0.4745   13 (56.5)    0.9 (0.4 to 2.2)   0.7872
   Asian                                                           15 (19.7)           0.7 (0.3 to 1.3)           0.2490   49 (64.5)    1.2 (0.7 to 2.3)   0.5108
   Other                                                           5 (17.2)            0.6 (0.2 to 1.6)           0.2772   17 (58.6)    1.0 (0.4 to 2.2)   0.9251
  Ethnicity                                                                                                                                                
   Hispanic (ref)                                                  24 (31.2)                                               42 (54.5)                       
   Non-Hispanic                                                    31 (20.7)           0.6 (0.3 to 1.1)           0.0821   96 (64.0)    1.5 (0.8 to 2.6)   0.1681
  Age at randomisation (years)                                                                                                                             
   ≤20 (ref)                                                       14 (40.0)                                               20 (57.1)                       
   \>20 and ≤30                                                    18 (24.7)           0.5 (0.2 to 1.2)           0.1051   38 (52.1)    0.8 (0.4 to 1.8)   0.6199
   \>30 and ≤40                                                    17 (22.1)           0.4 (0.2 to 1.0)           0.0524   51 (66.2)    1.5 (0.6 to 3.3)   0.3557
   \>40                                                            6 (14.3)            0.3 (0.1 to 0.7)           0.0133   29 (69.0)    1.7 (0.7 to 4.3)   0.2812
  Biopsy class                                                                                                                                             
   III/IV (ref)                                                    38 (22.5)                                               105 (62.1)                      
   III/V or IV/V                                                   8 (34.8)            1.8 (0.7 to 4.7)           0.1998   11 (47.8)    0.6 (0.2 to 1.3)   0.1924
   V                                                               9 (25.7)            1.2 (0.5 to 2.8)           0.6799   22 (62.9)    1.0 (0.5 to 2.2)   0.9356
  Lupus nephritis duration (years)                                                                                                                         
   ≤1 (ref)                                                        38 (24.5)                                               95 (61.3)                       
   \>1 and \<5                                                     6 (19.4)            0.7 (0.3 to 1.9)           0.5383   19 (61.3)    1.0 (0.5 to 2.2)   \>0.9999
   ≥5                                                              11 (26.8)           1.1 (0.5 to 2.5)           0.7611   24 (58.5)    0.9 (0.4 to 1.8)   0.7482
  eGFR baseline (mL/min/1.73 m^2^)                                                                                                                         
   \<90 (ref)                                                      31 (23.7)                                               76 (58.0)                       
   ≥90                                                             24 (25.0)           1.1 (0.6 to 2.0)           0.8165   62 (64.6)    1.3 (0.8 to 2.3)   0.3171
  Anti-dsDNA baseline (IU/mL)                                                                                                                              
   Negative (\<30) (ref)                                           1 (7.1)                                                 8 (57.1)                        
   Positive (≥30)                                                  54 (26.0)           4.6 (0.6 to 35.7)          0.1484   128 (61.5)   1.2 (0.4 to 3.6)   0.7441
  C3 baseline (mg/dL)                                                                                                                                      
   ≥90 (ref)                                                       13 (26.0)                                               32 (64.0)                       
   \<90                                                            41 (23.6)           0.9 (0.4 to 1.8)           0.7227   106 (60.9)   0.9 (0.5 to 1.7)   0.6931
  C4 baseline (mg/dL)                                                                                                                                      
   ≥16 (ref)                                                       12 (17.1)                                               45 (64.3)                       
   \<16                                                            41 (26.8)           1.8 (0.9 to 3.6)           0.1189   92 (60.1)    0.8 (0.5 to 1.5)   0.5543
  UP/C baseline                                                                                                                                            
   ≤1 (ref)                                                        7 (21.2)                                                23 (69.7)                       
   \>1 and ≤3                                                      24 (27.3)           1.4 (0.5 to 3.6)           0.4976   59 (67.0)    0.9 (0.4 to 2.1)   0.7812
   \>3                                                             23 (22.5)           1.1 (0.4 to 2.8)           0.8725   54 (52.9)    0.5 (0.2 to 1.1)   0.0945
  Antimalarial treatment concomitantly during induction                                                                                                    
   Antimalarial (ref)                                              18 (21.4)                                               56 (66.7)                       
   No antimalarial                                                 37 (25.9)           1.3 (0.7 to 2.4)           0.4510   82 (57.3)    0.7 (0.4 to 1.2)   0.1657
  Lipid-modifying agent treatment concomitantly during induction                                                                                           
   Statin (ref)                                                    14 (26.9)                                               33 (63.5)                       
   No statin                                                       41 (23.4)           0.8 (0.4 to 1.7)           0.6059   105 (60.0)   0.9 (0.5 to 1.6)   0.6536
  Induction treatment                                                                                                                                      
   MMF (ref)                                                       34 (28.3)                                               72 (60.0)                       
   IVC                                                             21 (19.6)           0.6 (0.3 to 1.1)           0.1282   66 (61.7)    1.1 (0.6 to 1.8)   0.7956

Percentages show the proportion of TFs or complete remitters within the applicable covariate category.

Ref: reference category for ORs.

ORs \>1 imply more TF or complete remission in comparison category than in reference category.

Anti-dsDNA,, anti-double-stranded DNA; eGFR, estimated glomerular filtration rate; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; TF, treatment failure; UP/C, urine protein:creatinine ratio.

###### 

Significant covariates (p\<0.05) from the univariate analysis of early improvement (up to week 8 of induction) and end-of-induction parameters associated with renal outcome

                                               Treatment failure   Complete renal remission                                                                   
  -------------------------------------------- ------------------- -------------------------- ------------------ ---------- ----- -------- ------------------ --------
  Population: complete population (n=370)                                                                                                                     
   UP/C reduction by week 8                                                                                                                                   
    25% reduction (ref)                        63                  (35.2)                                                                                     
    No 25% reduction                           66                  (59.5)                     2.7 (1.7 to 4.4)   \<0.0001                                     
   Anti-dsDNA reduction by week 8                                                                                                                             
    Reduction (ref)                            19                  (27.1)                                                                                     
    No reduction                               114                 (50.4)                     2.7 (1.5 to 4.9)   0.0008                                       
   C3 normalisation by week 8                                                                                                                                 
    Normalisation (ref)                        27                  (29.7)                                                                                     
    No normalisation                           109                 (50.7)                     2.4 (1.4 to 4.1)   0.0008                                       
   C4 normalisation by week 8                                                                                                                                 
    Normalisation (ref)                        34                  (35.4)                                                                                     
    No normalisation                           101                 (48.3)                     1.7 (1.0 to 2.8)   0.0359                                       
   C3 and C4 normalisation by week 8                                                                                                                          
    Normalisation (ref)                        13                  (25.5)                                                                                     
    No normalisation                           123                 (48.2)                     2.7 (1.4 to 5.4)   0.0037                                       
  Population: maintenance population (n=227)                                                                                                                  
   Anti-dsDNA reduction by week 8                                                                                                                             
    Reduction (ref)                            6                   (10.5)                                                                                     
    No reduction                               47                  (29.6)                     3.6 (1.4 to 8.9)   0.0063                                       
   C4 at end induction                                                                                                                                        
    ≥16 (ref)                                  31                  (19.9)                                                                                     
    \<16                                       22                  (32.8)                     2.0 (1.0 to 3.8)   0.0388                                       
   UP/C at end induction                                                                                                                                      
    ≤1 (ref)                                                                                                                110   (67.9)                      
    \>1                                                                                                                     26    (42.6)   0.4 (0.2 to 0.6)   0.0007

Percentages show the proportion of TFs or complete remitters within the applicable covariate category.

Ref: reference category for ORs.

ORs \>1 imply more TF or complete remission in comparison category than in reference category.

No covariates met the p\<0.05 threshold for complete renal remission (complete population).

C3 (mg/dL) normalisation: change from \<90 at baseline to ≥90 at week 8.

C4 (mg/dL) normalisation: change from \<16 at baseline to ≥16 at week 8.

Anti-dsDNA (IU/mL) reduction: \>200 at baseline to ≤60 at week 8.

\>30 and ≤200 at baseline to ≤30 at week 8.

The numbers are reduced due to missing data. Each of the significant covariates in the complete population analysis contained approximately 300 of the 370 patients. The maintenance population analysis has less missing data with approximately 220 patients of the 227 contributing to the three analyses shown.

Anti-dsDNA, anti-double-stranded DNA; TF, treatment failure; UP/C, urine protein:creatinine ratio.

###### 

Multivariate analysis of baseline and early improvement parameters as predictors of renal outcome

  Analysis covariate                           Comparison                          OR (95% CI)         p Value
  -------------------------------------------- ----------------------------------- ------------------- ---------
  Population: complete population (n=370)                                                              
   TF                                                                                                  
    Anti-dsDNA at baseline                     Positive (≥30) vs negative (\<30)   12.7 (1.6 to 101)   0.0167
    UP/C reduction by week 8                   No 25% reduction vs 25% reduction   2.6 (1.5 to 4.4)    0.0006
    Anti-dsDNA reduction by week 8             No reduction vs reduction           2.9 (1.5 to 5.4)    0.0012
    C3 normalisation by week 8                 No normalisation vs normalisation   1.7 (0.9 to 3.1)    0.0766
   Complete renal remission                                                                            
    Ethnicity                                  Non-Hispanic vs Hispanic            2.0 (1.2 to 3.3)    0.0061
    C4 normalisation by week 8                 No normalisation vs normalisation   0.6 (0.4 to 1.1)    0.0794
  Population: maintenance population (n=227)                                                           
   TF                                                                                                  
    Induction treatment                        IVC vs MMF                          0.5 (0.2 to 1.0)    0.0500
    Antimalarial treatment                     No treatment vs treatment           2.4 (1.1 to 5.1)    0.0209
    UP/C reduction by week 8                   No 25% reduction vs 25% reduction   2.1 (1.0 to 4.2)    0.0471
    Anti-dsDNA reduction by week 8             No reduction vs reduction           3.5 (1.4 to 9.2)    0.0097
    Anti-dsDNA at end of induction             Positive (≥30) vs negative (\<30)   8.3 (1.0 to 66.0)   0.0464
   Complete renal remission                                                                            
    Age group\*                                \>20 and ≤30 vs ≤20                 0.7 (0.3 to 1.8)    0.4801
                                               \>30 and ≤40 vs ≤20                 1.8 (0.7 to 4.5)    0.2303
                                               \>40 vs ≤20                         2.7 (0.9 to 8.3)    0.0804
    eGFR at baseline                           ≥90 vs \<90                         2.0 (1.0 to 3.8)    0.0407
    UP/C at end induction                      \>1 vs ≤1                           0.3 (0.2 to 0.6)    0.0008

TF: ORs \>1 imply more failure in first factor level of comparison.

Complete renal remission: ORs \>1 imply more remission in first factor level of comparison.

C3 (mg/dL) normalisation: change from \<90 at baseline to ≥90 at week 8.

C4 (mg/dL) normalisation: change from \<16 at baseline to ≥16 at week 8.

Anti-dsDNA (IU/mL) reduction: \>200 at baseline to ≤60 at week 8.

\>30 and ≤200 at baseline to ≤30 at week 8.

\*Overall p value for age: p=0.0279.

Anti-dsDNA, anti-double-stranded DNA; eGFR, estimated glomerular filtration rate; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; TF, treatment failure; UP/C, urine protein:creatinine ratio.

Association of baseline factors with complete renal remission or TF {#s3a}
-------------------------------------------------------------------

Several baseline factors at the start of induction were independently associated with complete renal remission or TF during the maintenance phase ([table 5](#LUPUS2015000089TB5){ref-type="table"}). In the complete population of 370 patients, non-Hispanic ethnicity was the only baseline characteristic associated with complete renal remission. A total of 40% of non-Hispanic patients achieved renal remission compared with 32% of Hispanic patients (OR 2.0, 95% CI 1.2 to 3.3, p=0.0061). Also among the complete population, the presence of anti-dsDNA was the only baseline factor that was independently associated with TF. Only 7% (1/14) of patients who were negative for anti-dsDNA at the start of induction became TFs during maintenance therapy, compared with 50% of patients who were anti-dsDNA positive (OR 12.7, 95% CI 1.6 to 101.9, p=0.0167). Within the maintenance population of 227 patients, baseline eGFR ≥90 mL/min/1.73 m^2^ was independently associated with complete renal remission (65% vs 58%, OR 2.0, 95% CI 1.0 to 3.8, p=0.0407). Also within the maintenance population, induction treatment with IVC and treatment with antimalarials were independently associated with reduced risk of TF. A total of 19.6% of patients induced with IVC were TFs during the maintenance phase, compared with 28.3% of patients induced with MMF (OR 0.5, 95% CI 0.2 to 1.0, p=0.05). Patients who were not treated with antimalarial agents during induction were more likely to be TFs during the maintenance period (26% vs 21%, OR 2.4, 95% CI 1.1 to 5.1, p=0.0209).

None of the other baseline characteristics examined was independently associated with either complete renal remission or TF during the maintenance phase. These characteristics included race, age, duration of lupus nephritis, biopsy class, C3 concentration, C4 concentration, UP/C and statin use. Although not achieving statistical significance in the multivariate model, biopsy class was associated with complete remission and TF in the univariate analysis. Among the complete population of 370 patients ([table 2](#LUPUS2015000089TB2){ref-type="table"}), mixed proliferative and membranous biopsy were negatively associated with complete renal remission in that only 22% of patients with mixed class biopsy achieved a complete renal remission versus 40% of the pure class III or IV patients (OR 0.4, 95% CI 0.2 to 0.8, p=0.0161). A total of 70% of patients with biopsies containing mixed proliferative and membranous features (III/V or IV/V) became TFs, compared with 50% of patients with pure class III or IV (OR 2.4, 95% CI 1.2 to 4.5, p=0.0095). Lastly, in the univariate analysis of the maintenance population, patients with baseline age \>40 years were less likely to be TFs during the maintenance period. A total of 14% of patients \>40 years versus 40% of patients ≤20 years were TFs during maintenance (OR 0.3, 95% CI 0.1 to 0.7, p=0.0133). These comparisons did not achieve statistical significance in the multivariate analysis.

Changes in biological parameters during the induction phase and association with renal outcome in the maintenance phase {#s3b}
-----------------------------------------------------------------------------------------------------------------------

### Changes in anti-dsDNA {#s3b1}

Failure to reduce anti-dsDNA by week 8 of induction therapy was associated with TF during the maintenance phase in the multivariate analysis of both the complete and maintenance populations ([table 5](#LUPUS2015000089TB5){ref-type="table"}). Among patients in the complete population who did not have an early reduction in anti-dsDNA by week 8, 50% developed TF compared with 27% who did have an early reduction in anti-dsDNA (OR 2.9, 95% CI 1.5 to 5.4, p=0.0012). Among those in the maintenance population who did not have an early reduction in anti-dsDNA by week 8, 30% developed TF during the maintenance phase compared with 10% of patients who did have an early reduction in anti-dsDNA (OR 3.5, 95% CI 1.4 to 9.2, p=0.0097). Lastly, in the maintenance population, positive anti-dsDNA at the end of induction was associated with TF. Among patients in the maintenance population who were anti-dsDNA positive at the end of induction, 26.9% developed TF during the maintenance phase compared with 4.8% of patients who were anti-dsDNA negative at the end of induction (OR 8.3, 95% CI 1.0 to 66.0, p=0.0464).

### Changes in proteinuria {#s3b2}

Early changes in UP/C within 8 weeks and UP/C at the end of induction were independently associated with renal outcome ([table 5](#LUPUS2015000089TB5){ref-type="table"}). Among the complete population and the maintenance population, lack of reduction of UP/C by ≥25% within 8 weeks of induction was associated with TF. A total of 59% of patients in the complete population without UP/C reduction versus 35% with UP/C reduction were TFs (OR 2.6, 95% CI 1.5 to 4.4, p=0.0006). A total of 33% of patients in the maintenance population without UP/C reduction versus 21% with UP/C reduction were TFs (OR 2.1, 95% CI 1.0 to 4.2, p=0.0471). Lastly, among patients in the maintenance population who entered the maintenance phase with UP/C of \>1, 43% achieved complete renal remission. In contrast, 68% of patients with UP/C ≤1 achieved complete renal remission (OR 0.3, 95% CI 0.2 to 0.6, p=0.0008).

### Changes in complement levels {#s3b3}

While changes in complement levels during induction were not independently associated with clinical outcomes during maintenance (p\>0.05), a number of these measures did demonstrate association in the univariate analysis ([table 4](#LUPUS2015000089TB4){ref-type="table"}). C3 and C4 normalisation by week 8 (both individually and combined as a single measure of normalisation) showed association with TF in the complete population. Depending on the complement measure, patients who did not normalise complement had between 1.7 and 2.7 times the odds of TF compared with patients who did normalise complement. A similar magnitude of effect was seen in the analysis of the maintenance population for C4 level at the end of induction. A total of 33% of patients with C4 \<16 mg/dL versus 20% of patients with C4 ≥16 mg/dL at the end of induction were TFs during maintenance (OR 2.0, 95% CI 1.0 to 3.8, p=0.0388) ([table 4](#LUPUS2015000089TB4){ref-type="table"}).

Discussion {#s4}
==========

In this study, we analysed data from the ALMS of IVC versus MMF for induction treatment followed by MMF versus AZA for maintenance treatment of lupus nephritis. Our objectives were twofold: (1) to determine if baseline factors present at the beginning of induction were associated with renal outcome and (2) to determine if changes in biological factors in the early weeks of induction or by the end of induction were associated with renal outcome during a 36-month maintenance period. We studied the complete intent-to-treat population (complete population) as well as the population of patients who continued into the maintenance phase after having achieved a complete or partial renal response after induction treatment (maintenance population). It is important to note that patients who did not respond to the induction treatment regimen were *not* randomised into the maintenance phase. Thus, the patients in the maintenance phase were inherently different from those who started the trial in the induction phase. In order to mitigate this potential source of bias, we chose to analyse the complete population and the maintenance population separately and report the results for both populations. For purposes of the analysis, we made the conservative decision that those patients who were not randomised into the maintenance phase were assumed to have a treatment outcome of either TF or non-complete remission, as appropriate.

In the multivariate analysis of the complete population, only non-Hispanic ethnicity was independently associated with complete remission during the maintenance phase. Three factors were independently associated with TF: (1) anti-dsDNA positivity at baseline, (2) failure to reduce anti-dsDNA within 8 weeks of induction and (3) failure to reduce UP/C by at least 25% within 8 weeks of induction.

In the multivariate analysis of those patients who continued into the maintenance phase of the trial (the maintenance population), baseline eGFR ≥90 mL/min/1.73 m^2^ and UP/C ≤1 at the end of induction were independently associated with complete remission during the maintenance phase. Induction treatment with IVC was associated with a lower likelihood of TF, while lack of treatment with antimalarials, failure to reduce anti-dsDNA or UP/C within 8 weeks of induction, and positive anti-dsDNA at the end of induction were independently associated with TF.

Our current findings build upon those from our previous study in which we found that early reduction in proteinuria and early normalisation of complement were independently associated with renal response at 6 months.[@R2] Consistent with our previous findings, we have now shown that early improvement in proteinuria is independently associated with renal outcome during the 36-month maintenance phase following completion of induction therapy. Differing from our previous study, we found that early changes in complement levels were not independently associated with long-term renal outcome. Although we previously found that early reduction in anti-dsDNA was not predictive of response at 6 months, our current study demonstrates that changes in anti-dsDNA during induction are predictive of response during the longer maintenance phase. Given our extended period of observation out to 36 months after the completion of induction, it is not surprising that some of our results differ from our previous shorter-term study. It is well described and currently accepted that response to treatment of lupus nephritis continues to occur well beyond induction therapy. Thus, it is often difficult to draw a clear distinction between when induction treatment ends and maintenance treatment begins. For example, one study suggested that the median time to renal response with intravenous Cytoxan was 10 months.[@R6] A study of oral Cytoxan for induction treatment of lupus nephritis followed by MMF or AZA as maintenance therapy demonstrated that improvement in proteinuria and renal function continues well into the maintenance phase.[@R7] These observations highlight both the importance of long-term follow-up when assessing renal response to treatment in lupus nephritis trials and the somewhat arbitrary nature of our current definitions of disease response.

Our findings demonstrating a higher likelihood of renal remission in patients of non-Hispanic ethnicity in the complete population expand upon previous studies that have shown a greater incidence and worse prognosis in patients of Hispanic ethnicity with lupus nephritis.[@R8] [@R9] Our data showing a reduced likelihood of TF in patients in the maintenance population treated with antimalarials are consistent with the results of a study of patients with MMF-treated membranous lupus nephritis in which patients who received concomitant treatment with hydroxychloroquine were more likely to achieve renal remission by 12 months as compared with patients who did not receive hydroxychloroquine.[@R10] These results are consistent with a broader accumulating literature demonstrating the many benefits of treatment with antimalarials, including the reduction of flares and prevention of renal damage.[@R11] [@R12] Although ALMS showed similar efficacy of IVC and MMF, inducing a renal response at 6 months, our current study suggests that patients treated with IVC during induction are less likely to develop TF during maintenance. A similar observation was made in a subgroup analysis of the ALMS maintenance phase, in which there was a trend of reduced incidence of TF during maintenance in those patients who received IVC as the induction agent. This trend of improved efficacy with IVC was present in patients regardless of whether they received MMF or AZA during maintenance.[@R5] In our present analysis, the magnitude of the difference in response between the IVC and MMF groups is not profound enough to currently dictate individual patient treatment decisions. It is also important to recognise that various factors play a role in the choice of an induction agent for a particular patient, including the documented and perceived risks of a potential medication. However, these observations emphasise the importance of long-term renal outcome data in assessing the efficacy of induction regimens for the treatment of lupus nephritis.

Several other studies have examined predictors of renal response to treatment. Consistent with our findings, an early response to treatment as defined by proteinuria has been shown to be associated with improved long-term patient and renal survival. An analysis of 90 patients from the Euro-Lupus Nephritis Trial of low-dose IVC versus high-dose IVC for the induction treatment of lupus nephritis demonstrated that a decrease in serum creatinine and proteinuria of \<1 g at 6 months predicted a favourable renal outcome at 10 years.[@R13] Another study of 85 patients showed that change in proteinuria at 1 year was predictive of long-term renal survival and overall mortality.[@R14]

A strength of our study is that we used data from ALMS, a randomised controlled trial that collected data throughout a 36-month maintenance phase following a 6-month induction phase. ALMS is one of the largest controlled trials for the treatment of lupus nephritis. By including data from the 36-month maintenance phase, we expanded upon our previous manuscript using only the 6-month induction phase data. Similar to our previous manuscript, a limitation of our current study is the fact that it is a post hoc analysis.

In conclusion, using long-term data from the ALMS, we identified several factors during the induction phase that are associated with renal outcome during the maintenance phase. Because of the differing patient composition of the complete and maintenance populations, we analysed the two populations separately. The maintenance population was composed of only those patients who achieved a renal response at the end of the induction phase of the trial and continued into the maintenance phase of the trial. The data from both populations are presented separately in this manuscript.

Although our findings contribute to the understanding of predictors of renal outcome in lupus nephritis, we believe that the associations described in this study are not strong enough to directly impact therapeutic decision making in individual patients in the clinic. Better biomarkers are needed to achieve this important goal. Lastly, in future controlled trials of lupus nephritis, studying the factors identified in our present analysis in a prespecified fashion might serve to further elucidate their association with renal response to treatment.
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